Erik Ingelsson

Erik Ingelsson, MD, PhD, Professor, Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine

 

Research Description: Dr. Ingelsson has been doing conducting research in at the intersection of obesity, insulin resistance, type 2 diabetes and cardiovascular disease for the past decade. His research is translational and interdisciplinary, combining methods from molecular epidemiology - clinical -omics studies - with work in functional model systems. He has had a leading role in many of the large multi-center efforts to identify new loci associated with cardiovascular and metabolic traits over the past ten years, and has extensive experience from research on cardiovascular biomarkers and -omics methods, including development and use of prediction metrics and Mendelian randomization. In the past two years, he has also built a team working with characterization of loci established in GWAS using different functional model systems. Dr. Ingelsson is co-leader of the “Metabolism and Signaling in Diabetes” Research Affinity Group in the Stanford DRC.

Selected diabetes, obesity, metabolism publications in the past five yearsrelevant publications (Stanford DRC members highlighted in BOLD)::

  1. Berndt SI, Gustafsson S, Mägi R, Ganna A, [>300 authors], McCarthy MI, Speliotes EK, North KE, Loos RJ, Ingelsson E. Genome-Wide Meta-Analysis Identifies 11 New Loci for Anthropometric Traits and Provides Insights into Genetic Architecture. Nat Genet. 2013; 45(5):501-12.
     
  2. Locke AE*, Kahali B*, Berndt SI*, Justice AE*, Pers TH*, [>500 authors], North KE*, Ingelsson E*, Hirschhorn JN*, Loos RJ*, Speliotes EK*. Genetic Studies of Body Mass Index Yield New Insights for Obesity Biology. Nature. 2015; 518(7538):197-206.
     
  3. Dimas AS*, Lagou V*, Barker A*, Knowles JW*, Mägi R, [53 authors], Dupuis J, Watanabe RM*, Florez JC*, Ingelsson E*, McCarthy MI*, Prokopenko I* on behalf of the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators. Impact of Type 2 Diabetes Susceptibility Variants on Quantitative Glycemic Traits Reveals Mechanistic Heterogeneity. Diabetes. 2014; 63(6):2158-71.
     
  4. Ganna A, Salihovic S, Sundström J, Broeckling CD, Hedman ÅK, Magnusson PKE, Pedersen NL, Larsson A, Siegbahn A, Zilmer M, Prenni J, Ärnlöv J,  Lind L, Fall T, Ingelsson E. Large-scale Metabolomic Profiling Identifies Novel Biomarkers for Incident Coronary Heart Disease. PLoS Genet. 2014;10(12):e1004801.
     
  5. Knowles JW*, Xie W*, Zhang Z*, Chennemsetty I*, [31 authors], Laakso M, Hao K*, Ingelsson E*, Frayling TM*, Weedon MN*, Walker M*, Quertermous T.* Identification and Validation of N-Acetyltransferase 2 as an Insulin Sensitivity Gene. J Clin Invest. 2015; 125(4):1739-51.
     
  6. Fall T*, Xie W*, Poon W, Yaghootkar H, Magi R, GENESIS consortium, Knowles JW, Lyssenko V, Weedon M, Frayling TM*, Ingelsson E*. Using Genetic Variants to Assess the Relationship between Circulating Lipids and Type 2 Diabetes. Diabetes. 2015; 64(7):2676-84.